首页> 外文期刊>Atherosclerosis >Genetic variants in adipose triglyceride lipase influence lipid levels in familial combined hyperlipidemia.
【24h】

Genetic variants in adipose triglyceride lipase influence lipid levels in familial combined hyperlipidemia.

机译:甘油三酸酯脂肪酶的遗传变异影响家族性合并高脂血症的脂质水平。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE: Familial combined hyperlipidemia (FCHL) has been associated with abnormalities in fatty acid metabolism. The adipose triglyceride lipase (PNPLA2) plays a pivotal role in the turnover of fatty acids in adipose tissue and liver. This study was designed to evaluate whether selected PNPLA2 variants may influence the susceptibility to FCHL or its lipid-related traits. METHODS: Four SNPs within the PNPLA2 gene (rs7925131, rs7942159, rs66460720 and the nonsynonymous P481L) were selected based on previous association with decreased plasma levels of free fatty acids (FFA) and total triglycerides (TG) and their high frequency (MAF>0.25). These SNPs were genotyped in 214 FCHL individuals from 83 families and in 103 controls and the corresponding haplotypes were reconstructed. RESULTS: No association between individual SNPs and the FCHL trait was observed. However, two PNPLA2 haplotypes were associated with lower risk of FCHL (P<0.004 after Bonferroni's correction). Compared to the others, these haplotypes were related to lower TG (118.9 +/- 66.8 vs. 197.1 +/- 114.7 mg/dl; P=0.001) and higher HDL-C (62.3 +/- 15.8 vs. 51.0 +/- 15.0 mg/dl; P<0.005). In a subgroup of studied subjects (n=63) protective haplotypes were also associated with lower FFA levels (0.33 +/- 0.11 vs. 0.46 +/- 0.18 mEq/L; P<0.05). These effects were independent from age, BMI and HOMA(IR). CONCLUSION: These data demonstrate that variants within PNPLA2 may modulate the TG component of FCHL trait, thus implicating PNPLA2 as modifier gene in this lipid disorder. They also suggest a potential role of PNPLA2 in the metabolism of TG-rich lipoproteins.
机译:目的:家族性合并高脂血症(FCHL)与脂肪酸代谢异常有关。脂肪甘油三酸酯脂肪酶(PNPLA2)在脂肪组织和肝脏中脂肪酸的周转中起关键作用。这项研究旨在评估所选的PNPLA2变体是否会影响对FCHL或其脂质相关性状的易感性。方法:根据先前与血浆游离脂肪酸(FFA)和总甘油三酸酯(TG)含量降低及其高频率(MAF> 0.25)的关联,选择了PNPLA2基因内的四个SNP(rs7925131,rs7942159,rs66460720和非同义P481L)。 )。在来自83个家庭和103个对照的214个FCHL个体中对这些SNP进行了基因分型,并重建了相应的单倍型。结果:没有观察到单个SNP与FCHL性状之间的关联。但是,两种PNPLA2单倍型与较低的FCHL风险相关(Bonferroni校正后P <0.004)。与其他单倍型相比,这些单倍型与较低的TG(118.9 +/- 66.8与197.1 +/- 114.7 mg / dl; P = 0.001)和较高的HDL-C(62.3 +/- 15.8与51.0 +/-)有关。 15.0mg / dl; P <0.005)。在一组研究对象(n = 63)中,保护性单倍型也与较低的FFA水平相关(0.33 +/- 0.11 vs. 0.46 +/- 0.18 mEq / L; P <0.05)。这些影响与年龄,BMI和HOMA(IR)无关。结论:这些数据表明,PNPLA2内的变异可能调节FCHL性状的TG成分,从而暗示PNPLA2作为这种脂质疾病的修饰基因。他们还暗示了PNPLA2在富含TG的脂蛋白代谢中的潜在作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号